A case of autologous thrombofibrin clot use in a patient with post-burn persistent corneal erosion
https://doi.org/10.23873/2074-0506-2019-11-2-150-157
Abstract
The purpose. Using clinical observation, to study the feasibility of applying a coagulant and to assess its efficacy in the treatment of patients with post-burn erosion of the cornea.
Material and methods. The treatment was carried out in the Department of Trauma and Reconstructive Surgery, the Helmholtz Moscow Research Institute of Eye Diseases, Russia. Based on clinical test results, the patient, was diagnosed with post-burn persistent erosion of the cornea with sub-total cornea conjunctivization and: limbal stem cell deficiency (LSCD) in the right eye. The keratoprotective therapy conducted for several months turned ineffective. In order to activate the cornea regeneration process, the erosion site was covered with autologous thrombofibrin clot that had been obtained from the stabilized blood. Following a two-stage centrifugation of patient's stabilized blood, the plasma with the platelets were collected into a round-bottomed test-tube; and the chloride calcium activator was added. The clot was formed in the thermostat at a temperature of 37 С. The patient was given a local anesthesia, and the thrombofibrin clot was placed on the cornea surface and covered with an amniotic membrane. The membrane was fixed with a circular stitch along the limbus of the cornea.
Result. The patient was followed-up and showed positive changes over time in the form of a diminished erosion area at day 5 and a complete corneal epithelialization at day 14.
Summary. Our methodaimed at enhancing the reparative and regenerative processes in the cornea, reducing swelling, accelerating epithelialization, expanding transparency, and improving the optic characteristics thanks to less intensive opacity formation showed a high efficacy.
About the Authors
E. V. Fedoseeva
Moscow Helmholtz’s Research Institute of Eye Diseases
Russian Federation
Russian Federation
Ophthalmologist, Postgraduate of the Department of Trauma and Reconstructive Surgery,
14/19 Sadovaya-Chernogryazskaya St., Moscow 105062
E. V. Chentsova
Moscow Helmholtz’s Research Institute of Eye Diseases
Russian Federation
Russian Federation
Prof., Dr. Med. Sci., Head of the Department of Trauma and Reconstructive Surgery,
14/19 Sadovaya-Chernogryazskaya St., Moscow 105062
N. V. Borovkova
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Dr. Med. Sci., Head of the Scientific Department of Biotechnologies and Transfusiology,
3 Bolshaya Sukharevskaya Sq., Moscow 129090
I. N. Ponomarev
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Cand. Med. Sci., Researcher of the Department of Biotechnologies and Tranfusiology,
3 Bolshaya Sukharevskaya Sq., Moscow 129090
A. O. Petrova
Moscow Helmholtz’s Research Institute of Eye Diseases
Russian Federation
Russian Federation
Senior Researcher of the Department of Trauma and Reconstructive Surgery,
14/19 Sadovaya-Chernogryazskaya St., Moscow 105062
Yu. A. Pavlenko
Moscow Helmholtz’s Research Institute of Eye Diseases
Russian Federation
Russian Federation
Ophthalmologist, Postgraduate of the Ophthalmic Plastic Surgery and Ocular Prosthetics Department,
14/19 Sadovaya-Chernogryazskaya St., Moscow 105062
References
1. Dursun D., Kim M.C., Solomon A., Pflugfelder S.C. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132(1):8–13. PMID:11438047
2. Hope-Ross M.W., Chell P.B., Kervick G.N., et al. Oral tetracycline in the treatment of recurrent corneal erosions. Eye (Lond). 1994;8(4):384–388. PMID:7821456 DOI:10.1038/eye.1994.91
3. Buxton J.N., Fox M.L. Superficial epithelial keratectomy in the treatment of epithelial basement membrane dystrophy: a preliminary report. Arch Ophthalmol. 1983;101(3):392–395. PMID:6600925
4. Soong H.K., Farjo Q., Meyer R.F., Sugar A. Diamond burr superficial keratectomy for recurrent corneal erosions. Br J Ophthalmol. 2002;86(3):296–298. PMID:11864887
5. McLean E.N., MacRae S.M., Rich L.F. Recurrent erosion: treatment by anterior stromal puncture. Ophthalmology. 1986;93:784–788. PMID:3737123
6. Kim S.Y., Ko B.Y. Evaluation of anterior stromal puncture using Nd:YAG laser for refractory recurrent corneal erosion. J Korean Ophthalmol Soc. 2015;56(3):331– 8. DOI:10.3341/jkos.2015.56.3.331
7. Choi M., Jung J.W., Seo K.Y., et al. Comparison of Nd: YAG laser versus conservative management in the treatment of recurrent corneal erosion. J Korean Ophthalmol Soc. 2015;56(5):687– 93. DOI:10.3341/jkos.2015.56.5.687
8. Forster W., Grewe S., Atzler U., et al. Phototherapeutic keratectomy in corneal diseases. Refract Corneal Surg. 1993;9(2 Suppl):85–90. PMID:8499387
9. Makarov P.V., Kugusheva A.E., Slepova O. S., et al. On persistent erosions of the corneal transplant.part 2. Russian ophthalmological journal. 2015;2:41–46. (In Russian).
10. Egorova N.S., Chentsova E.V., Borovkova N.V., et al.Experimental repair of deep corneal defects using a bioconstruct comprising a collagen type I matrix loaded with buccal epithelial cells. Transplantologiya. The Russian Journal of Transplantation. 2017;9(3):226–235. (In Russian). DOI:10.23873/2074-0506-2017-9-3-226-235
11. Egorova N.S., Chentsova E.V., Flora S.V., et al. Technologies of creation, evaluation of biocompatibility and safety of the collagen matrix in the bioengineering cell construction. Russian Ophthalmological Journal. 2017;10(2):71–77. (In Russian). DOI:10.21516/2072-0076-2017- 10-2-71-77
12. Nishida T., Nakamura M., Ofuji K., et al. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol. 1996;169(1):159– 166. PMID:8841432 DOI:10.1002/ (SICI)1097-4652(199610)169:13.0.CO;2-8
13. Van Setten G.B., Viinikka L., Tervo T., et al. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp. Ophthalmol. 1989;227(2):184–187. PMID:2785946
14. Gupta A., Monroy D., Ji Z., et al. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res. 1996;15(6):605–14. PMID:8670763
15. Liu L., Hartwig D., Harloff S., et al. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol. 2005;243(7):706– 714. PMID:15756576 DOI:10.1007/s00417-004-1106-5
16. Tsubota K., Goto E., Fujita H., et al. Treatment of dry eye by autologous serum application in Sjogren’s syndrome. Br J Ophthalmol. 1999;83(4):390–5. PMID:10434857
17. Ogawa Y., Okamoto S., Mori T., et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versushost disease. Bone Marrow Transplant. 2003;31(7):579–83. PMID:12692625 DOI:10.1038/sj.bmt.1703862
18. Noble B.A., Loh R.S., MacLennan S., et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88(5):647–52. PMID:15090417
19. Kojima T., Ishida R., Dogru M., et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005;139(2):242–246. PMID:15733983 DOI:10.1016/j.ajo.2004.08.040
20. Tananuvat N., Daniell M., Sullivan L.J., et al. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001;20(8):802–806. PMID:11685055
21. Tsubota K., Goto E., Shimmura S., Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999;106(10):1984–1989. PMID:10519596 DOI:10.1016/S0161-6420(99)90412-8
22. Poon A.C., Geerling G., Dart J.K., et al. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001;85(10):1188–1197. PMID:11567963
23. Young A.L., Cheng A.C., Ng H.K., et al. The use of autologous serum tears in persistent corneal epithelial defects. Eye (Lond). 2004;18(6):609– 614. PMID:15184926 DOI:10.1038/sj.eye.6700721
24. Jeng B.H., Dupps W.J. Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104–1108. PMID:19730088 DOI:10.1097/ICO.0b013e3181a2a7f6
25. Matsumoto Y., Dogru M., Goto E., et al. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology. 2004;111(6):1115–1120. PMID:15177961 DOI:10.1016/j.ophtha.2003.10.019
26. Alio J.L., Abad M., Artola A., et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114(7):1286–1293. e1. PMID:17324465 DOI:10.1016/j.ophtha.2006.10.044
27. Alio J.L., Pastor S., Ruiz-Colecha J., et al. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J Refract Surg. 2007;23(6):617–9. PMID:17598582
28. Loshkareva AO, MaychukD.Yu. Use of Platelet-rich Plasma in Patients with Chronic Corneal Erosions. Modern Technologies in Ophthalmology. 2016;4:131– 132. (In Russian).
29. Alio J.L., Arnalich-Montiel F., Rodriguez A.E. The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthalmology. Curr Pharm Biotechnol. 2012;13(7):1257–1265. PMID:21740369
Review
For citations:
Fedoseeva E.V., Chentsova E.V., Borovkova N.V., Ponomarev I.N., Petrova A.O., Pavlenko Yu.A. A case of autologous thrombofibrin clot use in a patient with post-burn persistent corneal erosion. Transplantologiya. The Russian Journal of Transplantation. 2019;11(2):150-157. https://doi.org/10.23873/2074-0506-2019-11-2-150-157
Views:
1037
Email this article 